GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. Shares of Hims & Hers (HIMS -3.58%) have been all over the map over the past few months as GLP-1s have gone from tailwind to headwind for the company's growth. But the bigger picture tells us that GLP-1s don't have a big impact on earnings, and the company's platform will grow no matter what happens to any single product. Travis Hoium breaks down the company's growth in this video. *Stock prices used were end-of-day ...

文章核心观点 - Hims & Hers 公司在过去一年中股价上涨260%,这并不令人意外 [1] - 这是一家正在重塑医疗保健,使其对用户更加实惠和便利的公司 [1] - 这是一个高风险/高回报的机会,这正是分析师寻找的内容 [1] 公司概况 - Hims & Hers 是一家上市公司,股票代码为NYSE: HIMS [1] - 公司正在重塑医疗保健,使其更加实惠和便利 [1] 行业分析 - 医疗保健行业正在经历变革,Hims & Hers 公司正在引领这一变革 [1] - 这是一个高风险/高回报的机会,吸引了分析师的关注 [1]

Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage. The change would be a boon for Hims & Hers, which makes copycat weight-loss drugs, and has benefited from the limited availability of some obesity medicines. With Monday's gains, Hims & Hers shares have more than doubled in value since the start of the year. Hims & Hers Health (HIMS) shares surg ...

Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA). The FDA announced it will allow compounding pharmacies to create and sell their own version of Eli Lilly's (LLY) weight-loss drug Mounjaro. In response, HIMS is enjoying a healthy bull gap, pacing toward its highest close since July, and has now broken above the resistant $20 level. The stock sports a 230% year-over-year gain, but stil ...

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? Hims & Hers (HIMS 4.71%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s. *Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024. ...

Look beyond the stock price at the business when shares are volatile. When the stock market is volatile and share prices tumble, opportunities arise to search for great businesses with stocks temporarily trading at bargain levels. When this happens, investors with a multiyear buy-and-hold strategy can shrewdly add such stocks to their portfolio while others sit on the sidelines. It's true that just because a stock is trading lower doesn't necessarily mean it has become a better buy. Sometimes, stocks trade ...

Consistently investing even moderate sums can grow your portfolio with time. Bull and bear markets come and go, and along with them come short-term investment opportunities. However, investors with a long-term buy-and-hold perspective can find opportunities in any market environment. And those opportunities don't always require a lot of available cash to tap into. Even with a more modest stash of cash -- say $500 -- to invest, you can find plenty of companies to put some or all of that amount into to benefi ...

文章核心观点 - 公司股价在最近一个交易日上涨10.1%,主要是由于公司加入标普小型股600指数的消息带来的投资者乐观情绪 [1] - 公司预计在即将发布的财报中,每股收益将同比增长250%,收入将同比增长67.1% [1] 公司信息 - 公司股票代码为HIMS,属于医疗信息系统行业 [2] - 公司当前的Zacks评级为3级(持有) [2] - 另一家同行业公司Fulgent Genetics(FLGT)在过去一个月内下跌2.4% [2][3] - Fulgent Genetics当前的Zacks评级也为3级(持有) [3]

文章核心观点 - 医疗保健行业通常被视为市场上最安全和最稳定的领域之一 [1] - 科技行业仍然受到青睐,但投资者正在将注意力从半导体行业转移到其他细分市场,如医疗科技 [1] - 医疗科技公司Hims & Hers Health Inc.(NYSE: HIMS)将医疗保健的稳定性与科技行业的高增长相结合,成为投资者关注的焦点 [1] 根据相关目录分别进行总结 Hims & Hers Health近期表现 - Hims & Hers股价在过去一周内上涨超过20.3%,主要是因为该公司被纳入标普600小型股指数 [2] - 这一纳入要求一些大型资金管理公司(如MSCI和Vanguard)在其投资组合中持有一定比例的Hims & Hers股票 [2] Hims & Hers股票的投资价值 - 尽管Hims & Hers股票已经吸引了超过3亿美元的机构资金,但华尔街分析师认为其仍有较大上涨空间 [3] - Needham & Co.给予Hims & Hers"买入"评级,目标价为24美元,较当前价格上涨23.1% [3] - 这一上涨空间主要源于公司的良好基本面,而不是受到Eli Lilly公司进入减肥GLP-1市场的影响 [4] - 主要机构投资者如Vanguard和Renaissance Technologies近期增持了Hims & Hers股票,增加了市场对其的信心 [5] Hims & Hers的估值溢价 - Hims & Hers的市净率(P/B)为12.0倍,远高于医疗行业4.8倍的平均水平,反映了市场对其未来增长的看好 [6] - 公司最新财报显示,收入同比增长52%至3.156亿美元,订阅用户同比增长43%至190万 [7] - 公司的订阅业务模式增加了其收入的稳定性和可预测性 [7] - 尽管公司尚未实现稳定的每股收益,但经营现金流从去年的2630万美元增长至7940万美元,显示其盈利潜力 [8] - 公司的高毛利率(超81%)也是其估值溢价的重要支撑 [8]

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 9, 2024S&P SmallCap 600 Ad ...